|
|
|
|
||
Hepdart Dec 3-7Global Strategies to Eliminate Hepatitis B (ICE-HBV) Peter Revill, Associate Professor Victorian Infectious Diseases Reference Laboratory, Australia Approaches to HBV Cure Marion Peters, MD University of California, USA Debate: Is Host Genome Integrated HBV Relevant? The Con Perspective Stephen Locarnini, MD, PhD Victorian Infectious Diseases Reference Laboratory, Australia The Pro Perspective Christian Brechot, MD, PhD Global Virus Network, USA Endpoints and New Targets for Curing Hepatitis B Stephen Locarnini, MD, PhD Victorian Infectious Diseases Reference Laboratory, Australia Core Antibody: anti-HBc What is the Core of the Story? Robert Gish, MD Hepatitis B Foundation, USA Challenges and Questions in the Cure for Chronic Hepatitis B Hepatitis B Foundation Session: Introduction Is There a Best Direct Acting Antiviral in Development? Is There a Best Host Acting Antiviral in Developtment (Epigenetic modifiers, cccDNA targeting)? Is There a Best Immunomodulator in Development? Discussion by Panel and Audience New directions towards functional cure of Chronic Hepatitis B Lawrence Blatt, PhD Janssen, USA Looking back to move forward: designing next-gen RNAi for best results in HBV Bruce Given, MD Arrowhead Pharmaceuticals, USA Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure Michael Sofia, PhD Arbutus Biopharma, USA |
return to message board, top of board |